---
schema_version: "secwatch.filing_event.v1"
accession: "0001485003-23-000099"
form_type: "8-K"
ticker: "CARM"
cik: "0001485003"
company_name: "Carisma Therapeutics Inc."
filed_at: "2023-03-06T23:59:59+00:00"
generated_at: "2026-06-18T11:26:03.931524+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sesen Bio to pay $0.36/share special dividend and issue CVR upon merger close on March 7

## Summary
- Special cash dividend of $75M (~$0.36/share) payable by March 10 to holders of record March 7, contingent on merger closing.
- Each share receives one Contingent Value Right for potential proceeds from sale of Vicineum/preclinical assets and Roche milestone.
- Merger with CARISMA Therapeutics approved by stockholders on March 2, expected to close March 7.
- Dividend and CVR issuance contingent on closing of merger with CARISMA.

## SEC filing metadata
- accession: 0001485003-23-000099
- form_type: 8-K
- ticker: CARM
- cik: 0001485003
- company_name: Carisma Therapeutics Inc.
- filed_at: 2023-03-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1485003/000148500323000099/0001485003-23-000099-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1485003/000148500323000099/sesn-20230306.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001485003-23-000099
- JSON: https://secwatch.observer/filing/0001485003-23-000099.json
- Plain text: https://secwatch.observer/filing/0001485003-23-000099.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.